XTMAB-16
Pulmonary Sarcoidosis
Phase 2Active
Key Facts
About Xentria
Xentria is a private, pre-revenue biotech company operating as a therapeutics developer and partnership facilitator. Its core business model involves forming collaborative partnerships to advance challenging drug candidates, with its lead asset, XTMAB-16, an anti-TNF monoclonal antibody, currently in Phase 2 development for pulmonary sarcoidosis. The company emphasizes adaptive development strategies, deep expertise in biologics, and a values-driven partnership approach to de-risk and accelerate programs for its collaborators.
View full company profileTherapeutic Areas
Other Pulmonary Sarcoidosis Drugs
| Drug | Company | Phase |
|---|---|---|
| SM001 (alidornase/Tigerase) | SarcoMed USA | Pre-clinical |
| Efzofitimod (ATYR1923) | aTyr Pharma | Phase 3 |